Recombinant Anti-EGFR x Anti-IGF1R Bispecific Antibody (Diabody-CH3) is a fusion protein of two diabodies connected together by a CH3 region. In a diabody, the two scFvs with short linkers are from anti-EGFR and anti-IGF1R antibodies. The VH and VL domains form an inter-chain pairing. The diabody with different specificities is fused to each of the CH3 chains, which results in 2+2 antigen-binding valency and extends the half-life of this BsAb. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Colorectal cancer; Cervical cancer; Breast cancer; Pancreatic cancer therapy.